A Multicountry, Multicentre, Non-interventional, Prospective Study toDetermine the Prevalence of EGFR Mutations in Patients With Early-stage,Surgically Resected, Non-squamous, Non-small Cell Lung Cancer

AstraZeneca Pharma India Limited0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1. Adult male or female patients =18 years old or ‘adults’ according to age of majority as
•defined by the local regulations
•2. Patient or next of kin/legal representative is willing and able to provide informed
•consent according to the local regulations, where applicable
•3. Patients with stage IA to IIIB (on the basis of pathologic criteria) NSCLC with
•adenocarcinoma, or mixed histology with an adenocarcinoma component who have
•undergone surgical resection of the tumour during the preceding 6 weeksa
•4. Availability of FFPE tissue specimen suitable for EGFRm testing (either the primary
•diagnostic sample or the surgically resected tumour specimen)
•5. Availability of medical records at the participating site detailing the initial diagnosis,
•staging, and surgical management of NSCLC

•1. Histology of the tumour is considered not to be of primary lung in origin
•2. Histology is pure squamous cell carcinoma, pure small cell carcinoma, or large cell
•carcinoma origin lacking any immunohistochemistry evidence of adenocarcinoma
•differentiation.

发起方